| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3265 |
| Trial ID | NCT05643742 |
| Disease | Mantle Cell Lymphoma | B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Follicular Lymphoma | Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Marginal Zone Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CTX112 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies |
| Year | 2022 |
| Country | United States |
| Company sponsor | CRISPR Therapeutics AG |
| Other ID(s) | CRSP-ONC-006 |
| Cohort 1 | |||||||||||
|
|||||||||||